News - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

126 to 150 of 293 results

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib

14-02-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Bayer and Janssen link with Portola for Xarelto antidote

06-02-2013

Germany's Bayer (BAYN: DE) and Janssen Pharmaceuticals, a part of US health care giant Johnson & Johnson…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalPortola PharmaceuticalsPRT4445Research

FDA approval of generic cancer drug Doxil is expected to help resolve shortage

06-02-2013

The US Food and Drug Administration has approved the first generic version of the cancer drug Doxil (doxorubicin…

DoxilGenericsJohnson & JohnsonLipodoxNorth AmericaOncologyRegulationSun Pharmaceutical Industries

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

European Commission enforcement action in pharmaceutical sector following sector inquiry

31-01-2013

Following its competition inquiry into the pharmaceutical sector of 2008/2009, the European Commission…

DuragesicEuropeGenericsJohnson & JohnsonLundbeckMarkets & MarketingPatentsPharmaceuticalServier

Johnson & Johnson 4th-qtr sales miss expectations and guidance disappoints

23-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday posted fourth-quarter and full-year 2012…

FinancialJohnson & JohnsonPharmaceutical

Expanded indication for Janssen's Zytiga cleared in EU

14-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International said Friday…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationZytiga

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11-01-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen

07-01-2013

Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Janssen's TB drug Sirturo gains US FDA approval

02-01-2013

The US Food and Drug Administration has granted accelerated approval for US health care major Johnson…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSirturo

Public Citizen urges FDA to reject accelerated approval for Janssen's bedaquiline

27-12-2012

The US Food and Drug Administration should not approve the anti-tuberculosis drug bedaquiline from Janssen,…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonNorth AmericaPharmaceuticalRegulation

Evotec in up to $175 million NMDA antagonist license deal with Janssen

19-12-2012

Germany's Evotec (EVT: TecDAX) has entered into a license agreement with Janssen Pharmaceuticals, a subsidiary…

EvotecJanssenJohnson & JohnsonLicensingNeurologicalPharmaceutical

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Janssen files Stelara for active psoriatic arthritis in USA and EU

07-12-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen yesterday submitted a supplemental…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationStelara Injection

Zeltia's Yondelis approved for sale in 10 new countries

04-12-2012

Pharma Mar, a subsidiary of Spain's Grupo Zeltia (ZEL: MC), says it has been advised by its licensee…

GlobalJanssenJohnson & JohnsonOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

126 to 150 of 293 results

Back to top